Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.
暂无分享，去创建一个
S. Leroy | P. Burgel | D. Grenet | B. Camara | R. Chiron | G. Rault | D. Hubert | J. Macey | S. Dominique | I. Honoré | R. Kanaan | L. Bassinet | A. Prevotat | Nadine Desmazes Dufeu
[1] D. Waltz,et al. Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[2] C. Goss,et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. , 2017, The Lancet. Respiratory medicine.
[3] D. Waltz,et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. , 2016, The Lancet. Respiratory medicine.
[4] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.